Although both agents can visualize PSMA tumors and metastatic lymph node/bone lesions, [99mTc]Tc-MIP1404 (also known as Tc-Trofolastat) is advantageous over [99mTc]Tc-MIP-1405 to detect PCa at early stages of the disease, and it is currently registered in a phase 3 clinical trial (NCT02615067) [194]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.